Dasatinib is a safe therapy for imatinib-resistant patients with chronic-phase CML

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷 / 9期
关键词：
D O I：
10.1038/ncponc0891
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：503 / 503
相关论文
共 50 条
  • [1] Dasatinib is effective in imatinib-resistant CML
    Cannell, Emma
    LANCET ONCOLOGY, 2007, 8 (04): : 286 - 286
  • [2] Dasatinib is active in imatinib-resistant and imatinib-intolerant patients with CML
    Nature Clinical Practice Oncology, 2007, 4 (6): : 328 - 328
  • [3] SIX-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING DASATINIB
    Rea, D.
    Vellenga, E.
    Junghanss, C.
    Baccarani, M.
    Kantarjian, H.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 80 - 80
  • [4] Five-year follow-up of patients with imatinib-resistant or - intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib
    Shah, N. P.
    Cortes, J. E.
    Schiffer, C. A.
    Guilhot, F.
    Brummendorf, T. H.
    Chen, A. C.
    Healey, D.
    Lambert, A.
    Saglio, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
    Gruber, F. X.
    Ernst, T.
    Porkka, K.
    Engh, R. A.
    Mikkola, I.
    Maier, J.
    Lange, T.
    Hochhaus, A.
    LEUKEMIA, 2012, 26 (01) : 172 - 177
  • [6] Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
    F X Gruber
    T Ernst
    K Porkka
    R A Engh
    I Mikkola
    J Maier
    T Lange
    A Hochhaus
    Leukemia, 2012, 26 : 172 - 177
  • [7] DASATINIB TREATMENT OF IMATINIB-RESISTANT AND IMATINIB-INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN A CHRONIC PHASE
    Vinogradova, O. Yu.
    Turkina, A. G.
    Vorontsova, A. V.
    Chelysheva, E. Yu.
    Gusarova, G. A.
    Kuznetsov, S. V.
    Goryacheva, S. R.
    Sokolova, M. A.
    Abakumov, E. M.
    Stakhina, O. V.
    Domracheva, E. V.
    Misyurin, A. V.
    Khoroshko, N. D.
    TERAPEVTICHESKII ARKHIV, 2009, 81 (07) : 41 - 46
  • [8] BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL
    Asano, E.
    Nita, M.
    Moellmann-Coelho, A.
    Rached, R.
    Donato, B.
    Rahal, E.
    VALUE IN HEALTH, 2009, 12 (07) : A262 - A262
  • [9] Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.
    Shah, Neil P.
    Kantarjian, Hagop
    Kim, Dong-Wook
    Hochhaus, Andreas
    Saglio, Giuseppe
    Guilhot, Francois
    Schiffer, Charles Alan
    Steegmann, Juan Luis
    Mohamed, Hesham
    Dejardin, David
    Healey, Diane I.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Management of imatinib-resistant CML patients
    Linke, Rolf
    Dempke, Wolfram
    ONKOLOGIE, 2007, 30 (11): : 574 - 580
12345